Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/5886
Title: Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Authors: Wanchoo, Rimda
Karam, Sabine
Uppal, Nupur N
Barta, Valerie S
Deray, Gilbert
Devoe, Craig
Launay-Vacher, Vincent
Jhaveri, Kenar D
Affiliations: Faculty of Medicine 
Keywords: Acute interstitial nephritis
Ipilimumab
Targeted therapies
Nivolumab
Onconephrology
Pembrolizumab
Renal failure
Issue Date: 2017
Publisher: National Library of Medicine
Part of: American Journal of Nephrology
Volume: 45
Issue: 2
Start page: 160
End page: 169
Abstract: 
Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers.
URI: https://scholarhub.balamand.edu.lb/handle/uob/5886
ISSN: 02508095
DOI: 10.1159/000455014
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record

SCOPUSTM   
Citations

284
checked on Nov 23, 2024

Record view(s)

38
checked on Nov 23, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.